<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03527316</url>
  </required_header>
  <id_info>
    <org_study_id>BASEC 2017-01947</org_study_id>
    <nct_id>NCT03527316</nct_id>
  </id_info>
  <brief_title>Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction</brief_title>
  <acronym>MFE</acronym>
  <official_title>Effect of MDMA (Serotonin Release) on Fear Extinction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serotonin and oxytocin play a role in fear conditioning and fear extinction learning,&#xD;
      psychological processes that are critically involved in psychiatric disorders such as&#xD;
      posttraumatic stress disorder (PTSD). Specifically, administration of oxytocin has been shown&#xD;
      to facilitate fear extinction in humans. Similarly, substances that release serotonin and&#xD;
      oxytocin such as MDMA have been shown to enhance the extinction of fear memory in animals.&#xD;
      However, there are no data on the effects of MDMA on fear extinction in humans. Therefore,&#xD;
      the primary aim of this study is to investigate the role of acute serotonin release in the&#xD;
      effects of fear extinction. MDMA will be used as pharmacological tool to induce serotonin&#xD;
      release in this study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 18, 2019</start_date>
  <completion_date type="Anticipated">December 24, 2021</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fear extinction measured by Skin conductance response</measure>
    <time_frame>12 months</time_frame>
    <description>a) Skin conductance response to conditioned stimuli</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fear extinction measured by Fear-potentiated startle</measure>
    <time_frame>12 months</time_frame>
    <description>b) Fear-potentiated startle to conditioned stimuli</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Oxytocin</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects measured by Visual analog scales</measure>
    <time_frame>12 months</time_frame>
    <description>Visual analog scales, 0-100, 0 for 'not at all' and 100 for 'extremely'</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects measured by Blood pressure</measure>
    <time_frame>12 months</time_frame>
    <description>Autonomic effects measured by vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects measured by Hearth rate</measure>
    <time_frame>12 months</time_frame>
    <description>Autonomic effects measured by vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic effects measured by Body temperature</measure>
    <time_frame>12 months</time_frame>
    <description>Autonomic effects measured by vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects measured by State-trait anxiety inventory for state (STAI-S)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of MDMA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MDMA, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, MDMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over within-subjects design with both treatment conditions, separated by a wash-out phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>125 mg MDMA per os, single dose</description>
    <arm_group_label>MDMA, Placebo</arm_group_label>
    <arm_group_label>Placebo, MDMA</arm_group_label>
    <other_name>3,4-Methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules containing mannitol looking identical to the other drugs.</description>
    <arm_group_label>MDMA, Placebo</arm_group_label>
    <arm_group_label>Placebo, MDMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age between 18 and 50 years.&#xD;
&#xD;
          -  Understanding of the German language.&#xD;
&#xD;
          -  Understanding the procedures and the risks associated with the study.&#xD;
&#xD;
          -  Participants must be willing to adhere to the protocol and sign the consent form.&#xD;
&#xD;
          -  Participants must be willing to refrain from taking illicit psychoactive substances&#xD;
             during the study.&#xD;
&#xD;
          -  Participants must be willing to drink only alcohol-free liquids and no coffee, black&#xD;
             or green tea, or energy drink after midnight of the evening before the study session,&#xD;
             as well as during the study day.&#xD;
&#xD;
          -  Participants must be willing not to drive a traffic vehicle or to operate machines&#xD;
             within 48 h after substance administration.&#xD;
&#xD;
          -  Body mass index 18-29 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic or acute medical condition&#xD;
&#xD;
          -  Hypertension (&gt;140/90 mmHg) or hypotension (SBP&lt;85 mmHg)&#xD;
&#xD;
          -  Current or previous major psychiatric disorder&#xD;
&#xD;
          -  Psychotic disorder in first-degree relatives&#xD;
&#xD;
          -  Illicit substance use (with the exception of cannabis) of more than 5 times or any&#xD;
             time within the previous month.&#xD;
&#xD;
          -  Participation in another clinical trial (currently or within the last 30 days)&#xD;
&#xD;
          -  Use of medications that may interfere with the effects of the study medications (any&#xD;
             psychiatric medications)&#xD;
&#xD;
          -  Tobacco smoking (&gt;10 cigarettes/day)&#xD;
&#xD;
          -  Consumption of alcoholic standard drinks (&gt;10/week or &gt;120 g ethanol/week)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias E Liechti, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology &amp; Toxicology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2018</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

